Page Comparison

Plan

Actual

Describe Intervention

Chosen intervention:

Clinical Pharmacist and students will chart review patients with DM, who are non-compliant for statin metric & review statin intensity..

Director of Performance Improvement, will perform chart audits on patients with LDL > 190

Plan for intervention:

List will be provided to this team to outreach, focusing on LDL >190.

Chosen Intervention:

Date when implemented: October 2023 (DM), November 2023 (LDL >190)

Updates:

Reach (#/% patients – or providers, for provider-facing interventions – who participated in intervention)

Reach of implementers/providers?

Planned:

3 (1 Clinical Pharmacist + 2 students)

Reach of implementers/providers?

Actual:

Reach of patients?

Planned:

80

Reach of patients?

Actual:

Over the months of September/October:

• LDL > 190 - 53 patients (of those 11 patients were corrected); sent telephone messages to 34 patients to schedule appts, remaining patients refused statins.

• DM: 300 patients total; 41 patients

Efficacy (Impact of intervention on important outcomes)

How will you measure that your intervention is working?

# patients of our planned reach that we actually reached. Of those, # patients switched to the compliant category.

Were you able to accurately measure how your intervention was working?

• Performed chart audits and monitored.

What outcomes do you expect?

We expect to identify patients who have refused statins in the past and will likely always remain “non-compliant”, but we will find more patients who are eligible for statins and we will be able to intervene.

What outcomes have you seen?

• Positive outcomes. Have new providers/reminding all providers for LDL > 190 need to be on statins/continuous education among providers

How will you ensure your intervention will be effective for your target population?

Measure outcome of # patients moved to compliant category and ideally, track therapeutic goals.

Did your intervention reach the target population?

• Absolutely!

What unintended consequences or outcomes might there be?

Expert Consensus still not published as guidelines yet, so it remains unclear which direction we should counsel providers in.

What unintended outcomes did you experience?

• Still need clarity around guidelines

Adoption (#/% and representativeness of staff and sites who implemented the intervention)

How did clinicians respond to interventions to intensify medication more rapidly/address therapeutic inertia?

Who will deliver the intervention (actually do the work)? Include staff and sites, if applicable.

Clinical Pharmacist and students followed by Providers implementing the decisions of statin Rx.

Who delivered the intervention? Did they have the skills and time needed to complete the intervention?

• Clinical pharmacist/pharmacy students/Director of Performance Improvement

• Having the pharmacy students allowed time to focus on this intervention.

How will you know if clinicians/care teams/sites used the intervention?

Tracking lists of patients

What proportion of the planned staff/sites implemented the intervention?

• Implemented across 8 sites

Were there any differences between care teams/sites who adopted the intervention best vs. others who did not (e.g., differences in staff types, capacity, etc.)?

• Newer providers had more opportunities d/t newer panels of patients and having more time to talk to patients. Older providers have more established panels, therefore making it difficult to have those conversation.

Implementation Fidelity (How closely the staff/sites followed the intervention design, delivered it as intended – also called fidelity to the intervention)

How will you know what adaptations or modifications were made during the intervention?

Patient list/tracking

How did you track modifications during the intervention?

• N/A

What might be some of the possible obstacles to consistent implementation?

Frequent chart review and education to providers

What were the barriers to consistent intervention implementation?

• Pharmacy students are seasonal, staffing challenges at times.

What costs and resources (including time and burden, not just money) need to be considered?

Time is the biggest one. Time to chart review, send messages with recommendations to providers, time to outreach to patients, etc.

What costs and resources (including time and burden, not just money) need to be considered?

• Time

How closely did the staff/sites follow the intervention design and deliver as intended?

Check all that apply:

•  Followed as designed
•  Followed with minor modifications
•  Followed somewhat as designed
•  Not followed as design
•  Delivered consistently/as intended
•  Delivered somewhat consistently/somewhat as intended
•  Delivered inconsistently/not as intended

Modifications made and other notes:

Maintenance (Extent to which intervention is part of routine practices and protocols)

What reinforcements will you put in place to sustain the intervention, if effective?

•  Protocols
•  Clinical decision support (alerts, order sets, templates, registries)
•  Policies
•  Regular training
•  Regular reports
•  Incentives
•  Other:

Explain:

What reinforcements did you put into place to sustain the intervention?

•  Protocols
•  Clinical decision support (alerts, order sets, templates, registries)
•  Policies
•  Regular training
•  Regular reports
•  Incentives
•  Other:

Explain:

How will you spread your intervention and lessons learned?

Review of the chart reviewed data overall with teams

How will you spread your intervention and lessons learned?

• Continuing to do annual provider education on statin therapy. Clinical pharmacist reviewing lists of pts sched to come in within 2 weeks among providers to make recommendations ahead of time to providers-send telephone encounter to providers.

What are likely modifications or adaptations that will need to be made to sustain the intervention over time (e.g., lower cost, different staff, reduced intensity, different settings)?

• Ensuring taking advantage of pharmacy students while there to review lists of patients.